Telix and Xiel Sign U.K. and Ireland Distribution Agreement for Illuccix®
Melbourne (Australia) and Liège (Belgium) – 29 March 2022. Telix announces agreement with Xiel for the distribution of Telix’s prostate cancer investigational imaging product, Illuccix® in the UK and Republic of Ireland.
Telix is pleased to announce it has signed an exclusive agreement with Xiel Limited (Xiel) for the distribution of Telix’s prostate cancer investigational imaging product, Illuccix® (TLX591-CDx, Kit for the preparation of 68Ga-PSMA-11 injection) in the United Kingdom (U.K.) and the Republic of Ireland.
Under the terms of the agreement, Xiel, a specialist distributor of Nuclear Medicine, Radiotherapy and Diagnostic Radiology technologies across the U.K. and Ireland will be the exclusive commercial distributor of Illuccix in the U.K. (a top 5 European market by GDP) and the Republic of Ireland for a period of three years from the national approval date.
Xiel Managing Director, Jack Knight stated, “PSMA PET imaging is emerging as the standard of care having recently been included in European and U.S. clinical practice guidelines. We are delighted to be adding Illuccix to our nuclear medicine portfolio and look forward to bringing this product to British and Irish men in need, upon regulatory approval. This commercial partnership with Telix will enable us to open the door to state-of-the-art PSMA imaging for the 61,000 men diagnosed with prostate cancer each year in the U.K. and the Republic of Ireland.”
Telix CEO EMEA, Richard Valeix added, “The U.K. and Ireland is one of Telix’s largest potential markets within the EMEA region, so we are pleased to have secured this agreement in anticipation of regulatory approval. Telix is creating a network of leading distribution partners to ensure we have a strong footprint to optimise our service to customer sites and ensure we can bring our imaging agent to patients across the region.”
To read the full ASX disclosure please click here.
To return to Telix’s homepage please click here.